+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Icatibant Acetate Market - Global Forecast 2026-2032- Product Image
Icatibant Acetate Market - Global Forecast 2026-2032- Product Image
Sale

Icatibant Acetate Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118352
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Icatibant Acetate Market is projected to reach USD 1.39 Billion in 2026. It is expected to continue growing at a CAGR of 12.15%, reaching USD 2.78 Billion by 2032.

Icatibant Acetate: Executive Overview of a Targeted Bradykinin-Mediated Care Market

Icatibant acetate is a bradykinin B2-receptor antagonist used primarily in the management of acute attacks associated with hereditary angioedema (HAE). Its clinical relevance stems from the need for rapid control of localized swelling that can affect the skin, gastrointestinal tract, or upper airway. Market development is shaped by diagnostic recognition, treatment access, emergency-care readiness, reimbursement, and patient familiarity with self-administration rather than by a single therapeutic factor.

Diagnosis, Home Treatment, and Care Pathways Are Reshaping the Landscape

The landscape is shifting toward earlier recognition of HAE, individualized attack-management plans, and greater use of home-based treatment where regulators, clinicians, and payers permit it. Improvements in genetic and complement-pathway testing can reduce diagnostic delay, while education for patients, families, emergency personnel, and pharmacists supports faster intervention. At the same time, safety monitoring, product handling requirements, supply continuity, and differentiation from other angioedema types remain central to responsible adoption.

Artificial Intelligence Is Strengthening Detection, Evidence Generation, and Care Coordination

Artificial intelligence can support this market by identifying patients with recurrent unexplained swelling from longitudinal clinical records, flagging patterns that warrant complement testing, and helping distinguish HAE-related events from alternative causes of angioedema. Natural-language processing may improve extraction of attack severity, treatment timing, and outcomes from clinical documentation, while predictive tools can assist triage and follow-up. These applications require representative data, clinical validation, privacy safeguards, and human oversight; AI should complement rather than replace specialist diagnosis or emergency assessment.

Regional Differences Reflect Diagnostic Capacity, Access, and Emergency Preparedness

In North America, established HAE awareness, specialist networks, and home-treatment pathways support access, although affordability and insurance authorization can remain important barriers. Europe combines sophisticated rare-disease infrastructure with variation in national reimbursement, testing availability, and treatment protocols. Asia-Pacific presents substantial opportunity for improved diagnosis and specialist education, alongside uneven access across health systems and geographies. Latin America is influenced by centralized procurement, specialist concentration, and reimbursement constraints. In the Middle East, tertiary-care capacity and cross-border referral networks coexist with differences in recognition and coverage. Africa faces pronounced variation in diagnostic services, specialist availability, medicine procurement, and emergency-care capacity, making foundational disease awareness particularly important.

Economic and Security Groupings Reveal Uneven Health-System Readiness

ASEAN markets differ considerably in rare-disease diagnosis, regulatory pathways, and reimbursement, with regional cooperation potentially improving training and referral systems. BRICS members span advanced and developing health infrastructures, creating varied conditions for testing, procurement, and patient support. The European Union benefits from cross-border rare-disease collaboration while retaining national decisions on pricing and reimbursement. G7 countries generally have stronger specialist capacity and pharmacovigilance systems, but access and affordability are not uniform. GCC states often possess well-resourced tertiary facilities, while referral dependence and population mobility influence continuity of care. NATO members include diverse health systems; preparedness for emergency treatment and interoperability of clinical guidance are relevant across the group.

Country-Level Priorities Range from Specialist Expansion to Affordability and Supply Reliability

Australia can build on specialist services and coordinated rare-disease care while addressing geographic access. Brazil and Mexico require stronger diagnostic pathways, public-sector coverage, and treatment availability beyond major centers. Canada and the United States have substantial clinical expertise, with payer policies, prior authorization, and regional distribution influencing practical access. China and India present large and diverse patient populations, making specialist training, diagnostic capacity, and reliable procurement important priorities. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established medical systems, but national or regional reimbursement rules, referral patterns, and guideline implementation shape patient experience. Russia’s access environment is influenced by healthcare-system geography, procurement, and specialist availability. Across all countries, emergency protocols and patient education remain essential because airway involvement can become life-threatening.

Industry Leaders Should Prioritize Verified Access, Responsible Evidence, and Patient Readiness

Leaders should align clinical education with clear diagnostic pathways and standardized emergency protocols, emphasizing appropriate use rather than indiscriminate treatment. Partnerships with specialists, laboratories, hospitals, patient organizations, and payers can improve testing, referral, reimbursement navigation, and continuity of supply. Evidence programs should capture time to treatment, attack resolution, safety, patient-reported outcomes, and real-world use across demographic and geographic groups. Digital tools, including AI-enabled support, should be validated prospectively and governed through transparent privacy and clinical-accountability frameworks. Operationally, resilient distribution, practical administration training, and equitable support for underserved populations should be treated as core elements of market strategy.

Methodology Combines Clinical, Regulatory, Access, and Health-System Evidence

This executive summary uses a qualitative, evidence-led framework focused on the clinical role and adoption environment for icatibant acetate. The assessment considers the mechanism and established therapeutic context, HAE diagnosis and care pathways, regulatory and reimbursement conditions, emergency preparedness, patient-support needs, regional health-system differences, and the potential contribution of artificial intelligence. Geographic interpretation is organized across the required regions, economic and security groupings, and countries. No market estimates, market shares, forecasts, or company-specific claims are included; conclusions should be validated against current clinical guidelines, regulatory documents, reimbursement policies, and peer-reviewed evidence before operational decisions are made.

Sustainable Progress Depends on Faster Recognition and Equitable Emergency Access

The central opportunity in icatibant acetate is to reduce the consequences of delayed recognition and treatment for people experiencing HAE attacks. Progress will depend on coordinated improvements in diagnosis, specialist referral, patient and caregiver capability, emergency response, reimbursement, and supply reliability. Artificial intelligence may strengthen these systems when carefully validated, but clinical governance and equitable access remain decisive. Industry leaders that connect evidence generation with practical care delivery will be best positioned to support safer, faster, and more consistent treatment across diverse health systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Icatibant Acetate Market, by Indication
7.1. Introduction
7.2. Hereditary Angioedema Type I
7.3. Hereditary Angioedema Type II
7.4. Hereditary Angioedema Type III
8. Icatibant Acetate Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous Injection
8.3. Subcutaneous Injection
9. Icatibant Acetate Market, by Dosage Form
9.1. Introduction
9.2. Cartridge
9.3. Pre-Filled Syringe
9.4. Prefilled Pen
10. Icatibant Acetate Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.3.1. Hybrid
10.3.2. Pure Play
10.4. Retail Pharmacies
10.4.1. Chain Pharmacies
10.4.2. Independent Pharmacies
11. Icatibant Acetate Market, by End User
11.1. Introduction
11.2. Home Healthcare Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Icatibant Acetate Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Icatibant Acetate Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Icatibant Acetate Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Apotex Inc.
16.2. Bachem AG
16.3. Biophore India Pharmaceuticals Pvt. Ltd.
16.4. ChemWerth Inc.
16.5. Cipla Limited
16.6. Dr. Reddy's Laboratories Ltd.
16.7. Guangzhou Tosun Pharmaceutical Co., Ltd.
16.8. Hetero Healthcare Limited
16.9. HRV Pharma
16.10. Lupin Limited
16.11. Mylan N.V.
16.12. Novartis AG
16.13. Sandoz International GmbH
16.14. Shenzhen JYMed Technology Co., Ltd.
16.15. Sun Pharmaceutical Industries Ltd.
16.16. Swedish Orphan Biovitrum AB
16.17. Takeda Pharmaceutical Company Limited
16.18. Tecoland Corporation
16.19. Teva Pharmaceutical Industries Ltd.
16.20. Torrent Pharmaceuticals Ltd.
16.21. Viatris Inc.
16.22. Yonsung Fine Chemicals Co., Ltd.
16.23. Zydus Cadila Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Icatibant Acetate Market, Years Considered for the Study
FIGURE 2. Global Icatibant Acetate Market, Research Design
FIGURE 3. Global Icatibant Acetate Market, Research Framework
FIGURE 4. Global Icatibant Acetate Market, Data Triangulation
FIGURE 5. Global Icatibant Acetate Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Icatibant Acetate Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Icatibant Acetate Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Icatibant Acetate Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Icatibant Acetate Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Icatibant Acetate Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global Icatibant Acetate Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Icatibant Acetate Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Icatibant Acetate Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Icatibant Acetate Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Icatibant Acetate Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Icatibant Acetate Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Icatibant Acetate Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Icatibant Acetate Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Icatibant Acetate Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Icatibant Acetate Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Icatibant Acetate Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Icatibant Acetate Market Segmentation & Coverage
TABLE 2. Global Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 3. Global Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Hereditary Angioedema Type I Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Hereditary Angioedema Type I Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Hereditary Angioedema Type I Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Hereditary Angioedema Type II Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Hereditary Angioedema Type II Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Hereditary Angioedema Type II Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Hereditary Angioedema Type III Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Hereditary Angioedema Type III Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Hereditary Angioedema Type III Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 14. Global Intravenous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Intravenous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Intravenous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 21. Global Cartridge Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Cartridge Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Cartridge Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Pre-Filled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Pre-Filled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Pre-Filled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Prefilled Pen Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Prefilled Pen Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Prefilled Pen Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 31. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Hybrid Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hybrid Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hybrid Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Pure Play Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Pure Play Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Pure Play Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Chain Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Chain Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Chain Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Independent Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Independent Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Independent Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Global Home Healthcare Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Home Healthcare Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Home Healthcare Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Icatibant Acetate Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Icatibant Acetate Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. North America Icatibant Acetate Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. North America Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 73. North America Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 74. North America Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 75. North America Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 76. North America Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 77. North America Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 78. North America Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Latin America Icatibant Acetate Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Latin America Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 81. Latin America Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 82. Latin America Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 83. Latin America Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Latin America Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 85. Latin America Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 86. Latin America Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Europe Icatibant Acetate Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Europe Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 89. Europe Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 90. Europe Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 91. Europe Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 92. Europe Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 93. Europe Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 94. Europe Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Middle East Icatibant Acetate Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Middle East Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 97. Middle East Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 98. Middle East Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 99. Middle East Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 100. Middle East Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 101. Middle East Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 102. Middle East Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. Africa Icatibant Acetate Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Africa Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 105. Africa Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 106. Africa Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 107. Africa Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 108. Africa Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 109. Africa Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 110. Africa Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. Global Icatibant Acetate Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. ASEAN Icatibant Acetate Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. ASEAN Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. ASEAN Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. ASEAN Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 116. ASEAN Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. ASEAN Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 118. ASEAN Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 119. ASEAN Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. GCC Icatibant Acetate Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. GCC Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. GCC Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 123. GCC Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 124. GCC Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. GCC Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 126. GCC Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 127. GCC Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. European Union Icatibant Acetate Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. European Union Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 130. European Union Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 131. European Union Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 132. European Union Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 133. European Union Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 134. European Union Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 135. European Union Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. BRICS Icatibant Acetate Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. BRICS Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 138. BRICS Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 139. BRICS Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 140. BRICS Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. BRICS Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 142. BRICS Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 143. BRICS Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. G7 Icatibant Acetate Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. G7 Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 146. G7 Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 147. G7 Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 148. G7 Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. G7 Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 150. G7 Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 151. G7 Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. NATO Icatibant Acetate Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. NATO Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 154. NATO Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 155. NATO Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 156. NATO Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. NATO Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 158. NATO Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 159. NATO Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Global Icatibant Acetate Market Size, by Country, 2017-2032 (USD Million)
TABLE 161. United States Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 162. United States Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 163. United States Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 164. United States Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 165. United States Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. United States Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 167. United States Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 168. United States Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Canada Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 170. Canada Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. Canada Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 172. Canada Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 173. Canada Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. Canada Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 175. Canada Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 176. Canada Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Mexico Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 178. Mexico Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. Mexico Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 180. Mexico Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 181. Mexico Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. Mexico Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 183. Mexico Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 184. Mexico Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Brazil Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 186. Brazil Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 187. Brazil Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. Brazil Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 189. Brazil Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. Brazil Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 191. Brazil Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 192. Brazil Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. United Kingdom Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 194. United Kingdom Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 195. United Kingdom Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 196. United Kingdom Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 197. United Kingdom Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. United Kingdom Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 199. United Kingdom Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 200. United Kingdom Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Germany Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 202. Germany Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 203. Germany Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 204. Germany Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 205. Germany Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. Germany Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 207. Germany Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 208. Germany Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. France Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 210. France Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 211. France Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 212. France Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 213. France Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. France Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 215. France Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 216. France Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Russia Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 218. Russia Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 219. Russia Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 220. Russia Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 221. Russia Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 222. Russia Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 223. Russia Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 224. Russia Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. Italy Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 226. Italy Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 227. Italy Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 228. Italy Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 229. Italy Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. Italy Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 231. Italy Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 232. Italy Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. Spain Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 234. Spain Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 235. Spain Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 236. Spain Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 237. Spain Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. Spain Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 239. Spain Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 240. Spain Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. China Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 242. China Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 243. China Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 244. China Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 245. China Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. China Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 247. China Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 248. China Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. India Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 250. India Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 251. India Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 252. India Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 253. India Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. India Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 255. India Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 256. India Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Japan Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 258. Japan Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 259. Japan Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 260. Japan Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 261. Japan Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 262. Japan Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 263. Japan Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 264. Japan Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. Australia Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 266. Australia Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. Australia Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 268. Australia Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 269. Australia Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 270. Australia Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 271. Australia Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 272. Australia Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 273. South Korea Icatibant Acetate Market Size, 2017-2032 (USD Million)
TABLE 274. South Korea Icatibant Acetate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 275. South Korea Icatibant Acetate Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 276. South Korea Icatibant Acetate Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 277. South Korea Icatibant Acetate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 278. South Korea Icatibant Acetate Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 279. South Korea Icatibant Acetate Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 280. South Korea Icatibant Acetate Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. Global Icatibant Acetate Market Share, by Key Player, 2025
TABLE 282. Global Icatibant Acetate Market, Key Experts

Companies Mentioned

  • Apotex Inc.
  • Bachem AG
  • Biophore India Pharmaceuticals Pvt. Ltd.
  • ChemWerth Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Guangzhou Tosun Pharmaceutical Co., Ltd.
  • Hetero Healthcare Limited
  • HRV Pharma
  • Lupin Limited
  • Mylan N.V.
  • Novartis AG
  • Sandoz International GmbH
  • Shenzhen JYMed Technology Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Tecoland Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Yonsung Fine Chemicals Co., Ltd.
  • Zydus Cadila Ltd.

Related Topics

Related Reports

Icatibant Acetate Injection Market - Global Forecast 2026-2032 - Product Image

Icatibant Acetate Injection Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032 - Product Image

Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Angioedema - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Angioedema - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Hereditary Angioedema Therapeutic Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Hereditary Angioedema Therapeutic Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report by Treatment, End Use, Region, and Growth Forecasts, 2026-2033 - Product Image

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report by Treatment, End Use, Region, and Growth Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.